PCAOB Deficiency Tracker
← Back to Explorer

De Visser Gray LLP

Canada · Triennially Inspected

Inspection year
2022
Report date
26-Jun-2023
PCAOB release
104-2023-101
Audits reviewed
3
Audits w/ Part I.A deficiencies
2
Part I.A deficiency rate
67%
Part I.A deficiencies
5
Part I.B deficiencies
10
Report
View PDF ↗

Deficiencies (5)

Grouped by issuer and in the same order as the PCAOB report, so each item ties back directly to the source.

Issuer A2 deficiencies

#AreaDeficiencyStandardFlags
1Significant AccountsThe firm did not evaluate beyond inquiry the reasonableness of certain significant assumptions used in the issuer's valuation of a significant account. (AS 2501.16)
Financial statement audit only
AS 2501.16
Significant risk
2Long-Lived AssetsTo substantively test long-lived asset additions the firm selected additions for testing that exceeded a monetary threshold. The firm did not perform any procedures to test the remaining population of long-lived asset additions. (AS 1105.27; AS 2301.08)
Financial statement audit only
AS 1105.27; AS 2301.8

Issuer B3 deficiencies

#AreaDeficiencyStandardFlags
1Exploration and Evaluation AssetsThe firm did not evaluate whether an exploration and evaluation asset had been acquired and the title had been transferred to the issuer. (AS 2301.08)
Financial statement audit only
AS 2301.8
Significant risk
2Exploration and Evaluation AssetsThe firm did not evaluate beyond inquiry the issuer's conclusion that there were no indicators of potential impairment for this asset even though there was evidence in the financial statements that an indicator of potential impairment existed. (AS 2301.08 and .11; AS 2810.03)
Financial statement audit only
AS 2301.8; AS 2301.11; AS 2810.3
Significant risk
3Exploration and Evaluation AssetsThe issuer developed an assumption that it used to capitalize costs related to other exploration and evaluation assets. The firm did not evaluate whether the issuer had a reasonable basis for this significant assumption. (AS 2501.16)
Financial statement audit only
AS 2501.16
Significant risk